Decision for or against Anti-PD-1 Treatment In Adjuvant Setting of Patients across Europe with Resected Stage IIB/IIC Melanoma
OBSERVATIONAL STUDY WITH MEDICINES
Clinical trial information
- Promoter: MERCK SHARP & DOHME DE ESPAÑA SA
- Execution start: 10/12/2024
- End of execution: 30/10/2025
- IP: SILVIA SEQUERO LOPEZ
